Bleeding disorders:
Indications for: CABLIVI
Treatment of acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Adult Dosage:
Administer upon initiation of plasma exchange therapy. 1st bolus IV inj requires administration by healthcare provider. Give subsequent SC inj (after proper training) into the abdomen; rotate inj sites. Avoid inj around the navel. Day 1: Initially 11mg bolus IV inj at least 15mins prior to plasma exchange, then 11mg SC inj after plasma exchange completion. Subsequent Days (during daily plasma exchange): 11mg SC inj once daily following plasma exchange; (after plasma exchange period): 11mg SC inj once daily continuing for 30 days following the last daily plasma exchange; may further extend treatment for max 28 days if signs of persistent underlying disease are present (eg, suppressed ADAMTS13 activity levels). Discontinue if >2 recurrences of aTTP during treatment.
Children Dosage:
Not established.
CABLIVI Warnings/Precautions:
Increased risk of bleeding; interrupt treatment if severe; monitor closely. Withhold treatment 7 days prior to elective surgery, dental procedures, or other invasive interventions. Severe hepatic impairment; monitor closely. Coagulopathy (eg, hemophilia, other coagulation factor deficiencies). Pregnancy, neonates: monitor closely. Nursing mothers.
CABLIVI Classification:
von Willebrand factor (vWF)-directed antibody fragment.
CABLIVI Interactions:
Avoid concomitant anticoagulants or antiplatelet agents; may increase risk of bleeding; monitor closely if needed.
Adverse Reactions:
Epistaxis, headache, gingival bleeding, fatigue, urticaria, pyrexia, paresthesia, dyspnea.
Generic Drug Availability:
NO
How Supplied:
Single-dose vial—1 (w. diluent, supplies)
